Lupus Nephritis
FDA fast tracks CAR T-cell therapy for refractory lupus in anticipation of phase 1 trial
The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.
Infections account for majority of in-hospital deaths in childhood lupus
Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.
FDA approves IND application for Eque-cel T-cell therapy in SLE, lupus nephritis
The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.
Renal, cardiovascular risks lower in patients with lupus using metformin
Metformin may protect against the progression of adverse renal and cardiovascular outcomes in patients systemic lupus erythematosus, including lupus nephritis and infarction, according to data published in ACR Open Rheumatology.